Opinion
C.A. No. B-03-222.
September 16, 2005
OPINION AND ORDER
BE IT REMEMBERED that on September 16, 2005, having received Plaintiffs' Unopposed Motion to Dismiss Dow Chemical Company [Dkt. No. 82] and Plaintiffs' Notice of Dismissal of all claims against all remaining Defendants [Dkt. No. 83], the Court DENIED AS MOOT the following pending motions: Sigma Aldrich's Motion to Dismiss [Dkt. No. 3]; Defendants' Motion to Dismiss [Dkt. No. 6]; Defendant Dow Chemical Company's Motion Dismiss [Dkt. Nos. 8-1 9-1]; Defendant Dow Chemical Company's Motion for Summary Judgment [Dkt. No. 9-2]; Defendant Eli Lilly's Motion to Dismiss [Dkt. No. 11-1]; Plaintiffs' Motion to Remand [Dkt. No. 16]; Defendant Sigma Aldrich's Motion to Dismiss Plaintiffs' First Amended Complaint [Dkt. No. 24]; Defendant Eli Lilly's Motion to Strike Plaintiffs' First Amended Complaint [Dkt. No. 28]; Defendants' Motion for Leave to File Notice of Supplemental Authority [Dkt. No. 50]; Vaccine Defendants' Renewed Motion to Dismiss [Dkt. No. 51]; Defendant Glaxosmithkline's Motion for Leave to File Supplemental Memorandum of Law in Opposition to Plaintiffs' Motion to Remand [Dkt. No. 65]; Defendant Glaxosmithkline's Motion for Leave to File Supplemental Status Report [Dkt. No. 67]; and all renewed motions that reiterate arguments already presented to the Court [Dkt. Nos. 72, 75, 76, 77 79].
DONE.